Semaglutide Reduced Liver Fat in Obesity Study
Adults with obesity saw significant reductions in liver fat after 72 weeks of treatment with semaglutide.
Updated on Oct. 6, 2026 in Weight Loss
Live Poll
Would you consider using weight-loss medication to treat metabolic liver conditions if recommended by a doctor?
Researchers have reported that semaglutide effectively lowered liver fat in adults with obesity. The findings were presented at the European Association for the Study of Diabetes Annual Meeting 2026.
Why it matters
Reducing hepatic steatosis is a key clinical goal for metabolic health, and this data helps evaluate how weight management regimens impact liver fat levels in those without diabetes.
In an exploratory analysis of 55 participants using magnetic resonance imaging, mean liver fat dropped from 8.8% to 3.1% over 72 weeks. These findings build upon broader STEP UP trial data, which enrolled over 1,900 adults to measure weight and metabolic outcomes.
The players
Novo Nordisk
A global pharmaceutical company focused on diabetes care and treatments for obesity and metabolic diseases.
The details
The study utilized magnetic resonance imaging-proton density fat fraction to quantify changes in hepatic steatosis. Participants received weekly injections of semaglutide at doses of 2.4 mg or 7.2 mg. This pharmacological approach mimics the action of GLP-1, a hormone that regulates appetite and metabolic processes, leading to significant weight reduction and subsequent decrease in ectopic fat storage within the liver.
Timeline
The STEP UP and STEP UP T2D trials were published in 2025.
Novo Nordisk released the STEP UP analysis findings on October 1, 2026.
The treatment period for the STEP UP trials concluded at week 72.
Part 2 results of the ESSENCE trial are expected in 2029.
Health Landscape
This analysis contributes to the growing body of evidence regarding the metabolic effects of high-dose GLP-1 receptor agonists. It marks an interim step in the broader evaluation of these therapies, providing clinical data ahead of the anticipated ESSENCE trial results.
If you are managing obesity, these findings highlight the potential metabolic benefits of weight management therapies on liver health. Discuss your specific liver health profile and any current treatment options with your physician to see if they are appropriate for your care plan.
The takeaway
Semaglutide has shown a significant ability to reduce liver fat in adults with obesity as part of a comprehensive weight management regimen. Tracking metabolic markers like liver fat during clinical care is a valuable step for patients and physicians to monitor overall health progress.
Further reading
For more on the latest research in metabolic health, visit the Weight Loss section.
More information
Review the official findings in the Novo Nordisk clinical trial news release.
Source note: This article includes information reported by Pharmacytimes.
Live Poll
Would you consider using weight-loss medication to treat metabolic liver conditions if recommended by a doctor?
